Tarsus to buy Alkeus in deal worth about $450 million upfront
Reuters2026/08/06 11:14- Tarsus agreed to buy privately held Alkeus Pharmaceuticals, adding Phase 3 Stargardt disease candidate gildeuretinol (ALK-001) to its eye-care pipeline.
- Deal terms include about USD 450 million upfront, split into USD 270 million cash and USD 180 million in Tarsus common stock.
- Alkeus holders could receive up to USD 350 million in milestones tied to regulatory approval and first commercial sale.
- The transaction includes low single-digit, tiered descending royalties on gildeuretinol net sales.
- Top-line Phase 3 NORTHSTAR data are expected in 2H 2029; closing is expected in 2026, subject to customary conditions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nvidia completes the inference loop: partners with Equinix and Together AI to open model inference to enterprises
Nvidia has partnered with Equinix, the world's largest data center colocation provider, and AI inference platform Together AI, with each party handling distinct roles—Equinix provides colocation services, Together AI offers the inference platform, and Nvidia supplies GPUs and the software stack—to jointly deliver open model inference services for enterprise clients. This move marks Nvidia's expansion of its computing ecosystem from training to inference, completing a closed-loop offering.
British Pound drops to three-week low as hawkish BoJ and suspected intervention boost Yen
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
